Rome V Gallbladder and Sphincter of Oddi Disorders: Gastroenterology | May 2026

The Rome V Gallbladder and Sphincter of Oddi Disorders chapter substantially modernizes this field by moving away from historically overused functional labels and procedure-driven diagnosis toward a more restrictive, symptom-based, harm-minimizing approach. The major theme throughout the chapter is clear: these disorders have been over diagnosed, invasive interventions have been overused, and Rome V now prioritizes careful phenotyping, exclusion of structural disease, objective evidence of obstruction, and conservative management before procedural therapy.

1. Rome V Reframes Gallbladder and Sphincter Disorders as Over diagnosed, High-Risk Syndromes

One of the most important conceptual shifts in Rome V is the explicit acknowledgment that dysfunctional gallbladder disorder (DGBD) and sphincter of Oddi disorder (SOD) have historically been over diagnosed and overtreated. Rome V emphasizes that many patients previously labeled with gallbladder or sphincter dysfunction likely have a more typical disorder of gut–brain interaction (DGBI), not a primary pancreaticobiliary motor disorder.

This is a major conceptual shift because it fundamentally changes the threshold for:

diagnosing DGBD/SOD,

recommending cholecystectomy,

and performing ERCP.

Rome V repeatedly emphasizes minimizing harm, given that both cholecystectomy and ERCP carry meaningful procedural risk.

2. “Typical Biliary Pain” Is Now the Central Diagnostic Gatekeeper

Rome V makes typical biliary pain the cornerstone of diagnosis for both DGBD and biliary SOD.

This is arguably the single most important practical update in the chapter because symptom quality now drives diagnostic confidence more strongly than legacy functional testing.

Rome V Definition of Typical Biliary Pain

Pain in the epigastrium and/or right upper quadrant with all of the following:

acute onset,

lasts ≥20 minutes to several hours,

episodic (not daily continuous pain),

severe enough to interrupt activities or prompt urgent evaluation,

unrelated to bowel movements,

not relieved by acid suppression or positional change.

Supportive features:

nausea/vomiting,

radiation to back/right scapula,

postprandial occurrence,

nocturnal awakening.

Rome V specifically clarifies that biliary pain is typically steady, not colicky, and is often epigastric rather than strictly RUQ, correcting two longstanding clinical misconceptions. The pain-pattern figure on page 2 (Figure 1) is especially useful because it contrasts the sustained pattern of biliary pain with renal colic and intestinal colic.

3. Gallbladder Ejection Fraction (GBEF) Is No Longer a Rome Diagnostic Criterion for DGBD

This is one of the most practice-changing updates in the chapter.

Rome V removes gallbladder ejection fraction (GBEF) from the supportive diagnostic criteria for dysfunctional gallbladder disorder (DGBD) because evidence that cholescintigraphy predicts response to cholecystectomy remains weak and inconsistent.

The chapter is explicit that:

typical biliary pain predicts response to surgery better than cholescintigraphy, and

GBEF should no longer be treated as a primary diagnostic determinant.

This is one of the most important Rome V departures from older surgical practice.

4. DGBD Now Requires Watchful Waiting Before Surgery

A major Rome V change is the addition of a preoperative observation period for suspected DGBD.

Rome V now recommends that symptoms should persist despite a trial of conservative/nonoperative management before cholecystectomy is considered.

This is a major shift because it explicitly discourages reflex cholecystectomy.

The rationale is highly practical:

DGBD is benign,

does not cause life-threatening complications,

and symptoms may resolve spontaneously in up to 50% of patients.

Rome V therefore recommends a 3–6 month period of watchful waiting in most patients to reduce unnecessary cholecystectomy.

This is one of the most important harm-reduction changes in the chapter.

5. Cholecystectomy for DGBD Is Now Reserved for Strictly Selected Patients

Rome V takes a much more restrictive approach to cholecystectomy in DGBD.

Cholecystectomy is appropriate only when:

the patient clearly meets criteria for typical biliary pain,

structural disease is excluded,

symptoms persist after observation,

and symptom burden remains clinically meaningful.

This is a substantial narrowing of operative candidacy.

The evaluation algorithm on page 5 (Figure 3) is one of the most clinically useful additions because it formalizes:

exclusion of alternate etiologies,

nonoperative trial,

reassessment at 3–6 months,

and only then consideration of surgery.

6. Sphincter of Oddi Manometry Is No Longer Part of Rome Criteria

One of the most important technical changes in Rome V is the removal of sphincter of Oddi manometry from diagnostic criteria.

This is a major departure from historical practice.

Rome V removes manometry because it is:

poorly reproducible,

insufficiently sensitive,

not reliably predictive,

and no longer clinically justifiable in routine practice.

The chapter explicitly notes that sphincter manometry has now been largely abandoned in clinical practice.

This is one of the most consequential procedural de-escalations in Rome V.

7. Biliary SOD Type III Has Effectively Been Eliminated

Rome V effectively abandons Type III SOD.

This is one of the most important and practice-changing updates in the chapter.

Following the landmark EPISOD trial, patients with biliary-type pain but no objective evidence of biliary obstruction are no longer considered to have a primary sphincter disorder. Instead, these patients are now understood to most likely have another DGBI.

This is a major conceptual correction and substantially reduces inappropriate ERCP.

8. Biliary SOD Now Requires Objective Evidence of Obstruction

Rome V now applies the term biliary SOD only to patients with:

typical biliary pain,

elevated liver tests and/or biliary dilation,

and no stones or structural obstruction.

This is one of the most important diagnostic tightening measures in Rome V.

The implication is simple and clinically important:

No objective evidence of biliary obstruction = no biliary SOD diagnosis.

9. Supportive Tests for Biliary SOD Have Been Removed

Rome V removes the historical supportive tests for biliary SOD:

normal amylase/lipase,

sphincter manometry,

hepatobiliary scintigraphy.

These were removed because they lack sufficient diagnostic reliability or predictive value.

This reflects both evidence evolution and current real-world practice.

10. ERCP for Biliary SOD Is Now Far More Restrictive

Rome V strongly narrows the role of ERCP in suspected biliary SOD.

ERCP is now primarily reserved for:

patients with convincing biliary obstruction,

probable SO stenosis,

or clinically meaningful objective evidence suggesting true obstructive physiology.

The evaluation algorithm on page 8 (Figure 5) is especially important because it formalizes a graded approach:

exclude alternatives,

determine objective evidence burden,

assess confounders (opioids, somatization, intermittent vs static abnormalities),

and reserve ERCP for those with higher likelihood of benefit.

This is one of the most important procedural gatekeeping changes in Rome V.

11. Chronic Opioid Use Is a Major Confounder in Suspected Biliary SOD

Rome V explicitly highlights chronic opioid use as a major diagnostic confounder in biliary SOD.

This is clinically important because opioids may cause:

bile duct dilation,

sphincter spasm,

and biliary-type symptoms,

without true primary sphincter disease.

This is a highly relevant real-world caution and should directly influence ERCP decision-making.

12. Pancreatic SOD Is Now Restricted to Unexplained Recurrent Acute Pancreatitis (RAP)

This is one of the most important Rome V changes.

Rome V now restricts pancreatic SOD to patients with documented recurrent acute pancreatitis (RAP) after exclusion of other etiologies.

This is a major narrowing of the diagnosis.

Rome V explicitly states there is no evidence that pancreatic SOD causes isolated pancreatic pain in the absence of pancreatitis.

This effectively eliminates “pancreatic SOD” as an explanation for unexplained pancreatic-type pain alone.

13. EUS Is Now the Preferred Test in Suspected Pancreatic SOD

Rome V strongly prioritizes EUS in unexplained recurrent acute pancreatitis.

This is one of the most important practical recommendations in the pancreatic SOD section.

EUS is now the preferred modality to exclude:

occult stones/sludge,

ampullary lesions,

pancreatic neoplasia,

ductal abnormalities,

and chronic pancreatitis.

MRCP remains complementary (or an alternative where EUS is unavailable), but EUS is now the preferred first-line advanced test.

14. ERCP for Pancreatic SOD Remains Uncertain and Highly Selective

Rome V remains cautious regarding ERCP in pancreatic SOD.

Although observational studies suggest benefit in selected patients with recurrent pancreatitis, evidence remains inconsistent and high-quality randomized data remain insufficient.

Accordingly, Rome V recommends:

individualized decision-making,

conservative management when feasible,

and highly selective ERCP use given procedural risk.

Clinical Bottom Line

The Rome V Gallbladder and Sphincter of Oddi Disorders chapter is fundamentally a diagnostic de-escalation and procedural restraint document.

Its major advances are:

strict redefinition of typical biliary pain,

removal of GBEF as a diagnostic criterion for DGBD,

mandatory watchful waiting before cholecystectomy,

removal of sphincter manometry,

effective elimination of Type III SOD,

requirement for objective biliary obstruction in biliary SOD,

much stricter ERCP thresholds,

recognition of opioids as a major confounder, and

restriction of pancreatic SOD to unexplained recurrent acute pancreatitis.

The single most important Rome V message is this: diagnosis now depends less on legacy functional testing and far more on strict symptom phenotyping, objective evidence, and procedural restraint.